In the pharmacological treatment of COPD with bronchodilators, an increased risk of arrhythmia can be expected in patients with cardiac comorbidity, particularly when theophylline is used. The bronchodilators of first choice are inhaled anticholinergic agents, followed by inhaled 尾 2 -sympathomimetics....
with or without short-acting anticholinergics, are the initial bronchodilators for acute treatment of a COPD exacerbation. A systematic review of the route of delivery of short-acting bronchodilators found no significant differences in FEV 1 between using...
Bronchodilators play a pivotal role in the treatment of symptomatic patients with chronic obstructive pulmonary disease (COPD). Inhaled short-acting bronchodilators are currently recommended for rescue of symptoms in patients with mild disease, while inhaled long-acting bronchodilators are recommended as ...
Thus, we demonstrated that Ka promotes neuroinflammatory inhibition via the cooperation of ubiquitination and autophagy, suggesting that Ka is a promising therapeutic strategy for the treatment of NDDs.Abbreviations: 3-MA: 3-methyladenine; AAV: adeno-associated virus; ACTB: actin, beta; AIF1/IBA1:...
摘要: Summary Bronchodilators, inhaled corticosteroids and other anti-inflammatory agents form the basis of treatment to control the symptoms and progression of asthma and COPD. However, although the armoury of medications used for the two conditions is largely关键词:...
Treatment of Type A COPD: Exacerbator Phenotype with Emphysema or Chronic Bronchitis The treatment of this phenotype includes one or two bronchodilators from different therapeutic groups. The patients who do not present exacerbations do not have an indication for either anti-inflammatory or mucolytic ...
treatment of COPD, there is strong rationale for maximizing bronchodilation as an initial strategy to reduce exacerbation risk irrespective of patient phenotype. Therefore, in patients assessed as frequent exacerbators (>1 exacerbation/year) we propose initial bronchodilator treatment with a long-acting...
In light of the above it would be prudent to target systemic and local oxidative stress with agents that can modulate the antioxidants/ redox system or by boosting the endogenous levels of antioxidants for the treatment and management of COPD. Identification of various antioxidant agents, such as ...
In this direction the use of colchicine, a low cost drug used for many years for the treatment of diseases such as Bechet's disease, prevention and treatment of pericarditis and family Mediterranean fever, could be a valid therapeutic option. Colchicine's multiple effects with the reduction of ...
In addition to the well-known fixed-dose drug associations such as fluticasone propionate/salmeterol xinafoate and budesonide/formoterol fumarate, other newly developed ICS/LABA combinations are currently emerging as very interesting pharmacological options for COPD treatment. 展开 ...